DEA Reschedules the Cannabidiol Drug Epidiolex

October 30, 2018

 

The Department of Justice and Drug Enforcement Administration (DEA) announced that Epidiolex, the newly approved medication by the Food & Drug Administration (FDA), is being placed in schedule V of the Controlled Substances Act (CSA). A schedule V controlled substance is the lowest level, defined as those with a proven medical use and low potential for abuse. Epidolex is a plant-based cannabidiol formulation for the adjunct treatment of seizures associated with two severe forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome, in patients 2 years of age and older.

Certain drugs, substances, and chemicals used to make drugs are classified into five distinct categories or schedules depending upon the drug’s acceptable medical use and the drug’s abuse or dependency potential. The abuse rate is a determinate factor in the scheduling of the drug.

 

 

Please reload

Our Recent Posts

"Anna-Sophie Rommel, Veerle Bergink, Xiaoqin Liu, Trine Munk-Olsen, Nina Maren Molenaar

Journal of Clinical Psychiatry 2020 May 12, 81 (3)

OBJECTIVE: Re...

"Long-Term Effects of Intrauterine Exposure to Antidepressants on Physical, Neurodevelopmental, and Psychiatric Outcomes: A Systematic Review&quo...

May 21, 2020

Below is an updated consent for telehealth; you can obtain the official form from my assistant Eric Scott Kincaid.  I added in the following (listed a...

Updated Consent for Telehealth

March 24, 2020

Hi everyone,

I know you’re all closely watching the new developments in the COVID-19 pandemic and I imagine you’ve seen the recent guidelines that sugg...

COVID-19/coronavirus update

March 15, 2020

1/1
Please reload

Tags

I'm busy working on my blog posts. Watch this space!

Please reload

 

mark@markwwilsonmdpc.com

assistant@markwwilsonmdpc.com

(917) 441-2344

PayPal can be used to send payment for services:

©2018 by Mark W. Wilson, MD, PC. Proudly created with Wix.com